Prostate cancer remains a significant health concern for men worldwide, particularly in the United States, where it is the most commonly diagnosed cancer and the fifth leading cause of cancer death among men. The disease disproportionately affects African American men and can range from slow-growing, low-grade tumors to aggressive, fast-spreading cancers. Given this variability, accurate screening and early detection are crucial for effective management and treatment.
Table of Contents
The Limitations of Current Screening Methods
The most widely used prostate cancer screening methods are the prostate-specific antigen (PSA) blood test and digital rectal exam (DRE). However, these methods have limitations in their precision. While elevated PSA levels can indicate the presence of cancer, they can also be high due to non-cancerous conditions, low-grade cancers, or recent biopsies. This imprecision often leads to unnecessary biopsies, causing discomfort and potential complications for many men who do not actually have cancer that requires treatment.
Introducing MyProstateScore 2.0 (MPS2)
To address these challenges, researchers funded by the National Cancer Institute (NCI) have developed and validated a new prostate cancer urinary biomarker test called MyProstateScore version 2.0, or MPS2[1]. This innovative test is designed to help differentiate between men who should proceed to biopsy after an elevated PSA test and those who can safely wait.
Key Features of MPS2
- 18-gene test: MPS2 is an improvement over its predecessor, which used a two-gene algorithm.
- Non-invasive: The test requires only a urine sample collected after a digital rectal exam.
- High accuracy: MPS2 showed a 95% sensitivity and negative predictive value for Grade Group 2 cancers, and 99% for Grade Group 3 and above.
- Potential to reduce unnecessary biopsies: The analysis estimates that approximately 40% of unnecessary biopsies could be avoided using MPS2.
Development and Validation of MPS2
The development of MPS2 involved a rigorous process of gene selection and algorithm refinement:
- Researchers scanned over 58,000 potential genetic targets from RNA sequencing data.
- The panel was refined to 54 candidate genes, then further narrowed to 17 genetic risk markers plus one reference gene (KLK3).
- The final MPS2 algorithm combines these 18 markers with clinical factors such as age, race, and family history.
Validation of the test was conducted through the NCI Early Detection Research Network (EDRN), using urine samples from 743 patients across 11 academic sites. The results, published in JAMA Oncology, showed that MPS2 outperformed other validated prostate cancer biomarker tests in accurately identifying patients with cancer detected at biopsy.
Clinical Implications and Future Steps
The introduction of MPS2 represents a significant step forward in prostate cancer screening. Dr. Howard Parnes, chief of the NCI Division of Cancer Prevention’s Prostate and Urologic Cancer Research Group, notes that “The MPS2 has the potential to reduce unnecessary biopsies and is therefore an important step in the right direction”[1].
Path to Clinical Use
- Regulatory considerations: The test results will be submitted for consideration by the National Comprehensive Cancer Network (NCCN).
- Immediate availability: The test can be used by clinicians if samples are sent to a CLIA-certified reference laboratory.
- Reimbursement: LynxDx, the company founded to translate this test into clinical practice, is working on reimbursement through Medicare and private insurance.
- FDA approval: Ultimately, the U.S. Food and Drug Administration will need to review and approve MPS2 for public marketing.
Ongoing Research and Limitations
While the initial results are promising, researchers acknowledge some limitations and areas for further study:
- Racial diversity: The validation cohort included only 4% of samples from African American men. Additional studies with more diverse cohorts are planned.
- Integration with advanced imaging: The assay will be validated in populations screened with multiparametric MRI, which is becoming more common as a second-line assessment after PSA[1].
The Role of the Early Detection Research Network (EDRN)
The development and validation of MPS2 highlight the crucial role played by the NCI’s Early Detection Research Network. This collaborative program provides the infrastructure and resources necessary for the discovery, development, and validation of cancer biomarkers. By connecting multidisciplinary teams across the United States, EDRN facilitates the seamless transition of candidate markers through the development pipeline.
Conclusion
The MyProstateScore 2.0 test represents a significant advancement in prostate cancer screening. By providing a more accurate method to identify clinically significant prostate cancers, it has the potential to reduce unnecessary biopsies and improve patient care. As research continues and the test moves towards wider clinical use, it may play a crucial role in refining prostate cancer screening and management strategies, ultimately leading to better outcomes for patients.
References
- Voss, A. M. (2024). An Improved Prostate Cancer Biomarker Test May Help Men Avoid Unnecessary Biopsy. National Cancer Institute. https://prevention.cancer.gov/news-and-events/blog/improved-prostate-cancer-biomarker-test-may-help-men-avoid-unnecessary-biopsy
0 Comments